<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04148677</url>
  </required_header>
  <id_info>
    <org_study_id>M1-2019</org_study_id>
    <nct_id>NCT04148677</nct_id>
  </id_info>
  <brief_title>Protoves M1® Syrup in Controlling Adverse Event During HIVEC® Instillations</brief_title>
  <official_title>The Role of Protopine Associated With Nuciferine (Protoves M1® Syrup) in Controlling Adverse Event During HIVEC® Instillations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardarelli Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardarelli Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      100 patients with bladder cancer whose underwent Hyperthermic Intravesical Chemotherapy
      (HIVEC®) will be randomized in two groups (Group A: PROTOVES M1 SYRUP, Group B: NO
      TREATMENT). The aim of this study will be to analyse the role of two alkaloid, Protopine and
      Nuciferine (Protoves-M1 ®) in the prevention and the treatment of the low and mild grade
      adverse events related to the use of HIVEC® instillations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100 patients with bladder cancer whose underwent Hyperthermic Intravesical Chemotherapy
      (HIVEC®) will be randomized in two groups (Group A: PROTOVES M1 SYRUP, Group B: NO
      TREATMENT). The aim of this study will be to analyse the role of two alkaloid, Protopine and
      Nuciferine (Protoves-M1 ®) in the prevention and the treatment of the low and mild grade
      adverse events related to the use of HIVEC® instillations.

      At the baseline data on demographic and anthropometric features (age, weight, height, BMI),
      lifestyle characteristics (smoke, alcohol), any comorbidities (hypertension, diabetes
      mellitus, etc.) will be collected. All patients will be undergone to a clinical evaluation
      (comprised general, genital and urologic examination). Before starting the treatment, the
      following measurements will be collected: prostate volume by transrectal ultrasound, PSA,
      uroflowmetry (Qmax, Volume Voided, Post-Void Residual), IPSS (International Prostatic
      Symptoms Score) questionnaire, OverActive Bladder questionnaire-short form (OABq-SF) 6 and
      13, patient perception of intensity of urgency scale (PPIUS), and visual analogue scale
      (VAS). PSA and IPSS will be investigated only in male pts. In addition, the patient
      impression of improvement will be assessed. Improvement will be evaluated with the Patient
      Global Impression of Improvement questionnaire (PGI-I), a validated tool to estimate the
      improvement or the deterioration associated to the treatment.

      The primary endpoint was the evaluation of the efficacy of the therapy with Protoves-M1 in
      controlling of the irritative symptoms, including nocturia, urinary frequency, bladder pain,
      urgency and urge incontinence related to the chemo-hyperthermia treatment. The secondary
      endpoint evaluated was the influences of the treatment on the uroflowmetric parameters.

      After 1 and 6 weeks of therapy all patients will be undergone to a clinical and instrumental
      evaluation : Uroflow-Qmax (ml/s), Uroflow-Volume voided (ml),Uroflow-RPM (ml), IPSS total,
      OAB-q SF 6, OAB-q SF 13, PPIUS, PGI-I, VAS scale will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>IPSS total</measure>
    <time_frame>1 and 6 weeks</time_frame>
    <description>The International Prostate Symptom Score (I-PSS) is based on the answers to some questions concerning urinary symptoms and one question concerning quality of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OAB-q SF 6</measure>
    <time_frame>1 and 6 weeks</time_frame>
    <description>The OAB-q SF 6 is a questionnaire developed to evaluate the overactive bladder symptom and health-related quality of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OAB-q SF 13</measure>
    <time_frame>1 and 6 weeks</time_frame>
    <description>The OAB-q SF 6 is a questionnaire developed to evaluate the overactive bladder symptom and health-related quality of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PPIUS</measure>
    <time_frame>1 and 6 weeks</time_frame>
    <description>The PPIUS is a questionnaire developed to evaluate the patient perception of intensity of urgency</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PGI-1</measure>
    <time_frame>1 and 6 weeks</time_frame>
    <description>PGI-I is a validated tool to estimate the improvement or the deterioration associated to the treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VAS scale</measure>
    <time_frame>1 and 6 weeks</time_frame>
    <description>Visual analogue scales (VAS) are 10-cm lines anchored at the ends by words that define the bounds of various pain dimensions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Qmax</measure>
    <time_frame>1 and 6 weeks</time_frame>
    <description>Qmax (ml/s) is the maximum flow rate at uroflowmetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume voided</measure>
    <time_frame>1 and 6 weeks</time_frame>
    <description>Volume voided (ml) at uroflowmetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RPM</measure>
    <time_frame>1 and 6 weeks</time_frame>
    <description>Post-Void residual (ml) measures the amount of urine left in the bladder after urination.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>LUTS</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Protoves M1® syrup</arm_group_label>
    <description>A combination of two alkaloid, Protopine and Nuciferine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <description>Patients will not receive a treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Protoves M1®</intervention_name>
    <description>A combination of two alkaloid, Protopine and Nuciferine (Protoves-M1 ®)</description>
    <arm_group_label>Protoves M1® syrup</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who referred to a general hospital to receive endoscopic treatment for bladder
        cancer (TURB) and then the endovescical chemioprofilaxis.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intermediate-and high-risk NMIBC (non-muscle invasive bladder cancer) patients.

          -  Therapeutic program of HIVEC® (Recirculant hyperthermic IntraVEsical chemotherapy).

          -  Must be able to drink a syrup.

        Exclusion Criteria:

          -  Uncontrolled underlying diseases (ASA III or IV)

          -  Post void residual urine ≥ 100 ml

          -  Bleeding tendency

          -  Drug abuse

          -  Chronic pelvic pain

          -  Urinary tract infection

          -  Neurological disease

          -  Bladder lithiasis

          -  Renal or liver failure

          -  Tachycardia and heart failure.

          -  Male patients with lower urinary tract symptoms (LUTS) and benign prostatic
             hyperplasia (BPH)with abnormal values of uroflowmetry

          -  Male patients with lower urinary tract symptoms (LUTS) that assume medical treatment
             for BPH.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Chiancone</last_name>
    <role>Principal Investigator</role>
    <affiliation>AORN A.Cardarelli Urology Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Chiancone</last_name>
    <phone>00393408639711</phone>
    <email>francescok86@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Sousa A, Piñeiro I, Rodríguez S, Aparici V, Monserrat V, Neira P, Carro E, Murias C, Uribarri C. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer. Int J Hyperthermia. 2016 Jun;32(4):374-80. doi: 10.3109/02656736.2016.1142618. Epub 2016 Feb 25.</citation>
    <PMID>26915466</PMID>
  </reference>
  <reference>
    <citation>Ustünes L, Laekeman GM, Gözler B, Vlietinck AJ, Ozer A, Herman AG. In vitro study of the anticholinergic and antihistaminic activities of protopine and some derivatives. J Nat Prod. 1988 Sep-Oct;51(5):1021-2.</citation>
    <PMID>2904975</PMID>
  </reference>
  <reference>
    <citation>Fedurco M, Gregorová J, Šebrlová K, Kantorová J, Peš O, Baur R, Sigel E, Táborská E. Modulatory Effects of Eschscholzia californica Alkaloids on Recombinant GABAA Receptors. Biochem Res Int. 2015;2015:617620. doi: 10.1155/2015/617620. Epub 2015 Oct 5.</citation>
    <PMID>26509084</PMID>
  </reference>
  <reference>
    <citation>Zhang C, Deng J, Liu D, Tuo X, Yu Y, Yang H, Wang N. Nuciferine Inhibits Proinflammatory Cytokines via the PPARs in LPS-Induced RAW264.7 Cells. Molecules. 2018 Oct 22;23(10). pii: E2723. doi: 10.3390/molecules23102723.</citation>
    <PMID>30360404</PMID>
  </reference>
  <reference>
    <citation>Wang MX, Zhao XJ, Chen TY, Liu YL, Jiao RQ, Zhang JH, Ma CH, Liu JH, Pan Y, Kong LD. Nuciferine Alleviates Renal Injury by Inhibiting Inflammatory Responses in Fructose-Fed Rats. J Agric Food Chem. 2016 Oct 26;64(42):7899-7910. doi: 10.1021/acs.jafc.6b03031. Epub 2016 Oct 18.</citation>
    <PMID>27718563</PMID>
  </reference>
  <reference>
    <citation>Dmochowski R. Antimuscarinic therapy in men with lower urinary tract symptoms: what is the evidence? Curr Urol Rep. 2006 Nov;7(6):462-7. Review.</citation>
    <PMID>17052442</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cardarelli Hospital</investigator_affiliation>
    <investigator_full_name>Francesco Chiancone</investigator_full_name>
    <investigator_title>Assistant Medical Director, Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

